No House member has disclosed a TXG trade since 2025.
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 21, 2026 | Suliman ShehnaazDirector | Sale at price 78.20 - 82.28 per share. | 5.7K | $464.67K |
| Sep 21, 2026 | Saxonov Serge WilsonChief Executive Officer | Sale at price 78.23 - 82.36 per share. | 25K | $2.03M |
| Sep 8, 2026 | Taich AdamChief Financial Officer | Sale at price 63.68 - 65.26 per share. | 46.4K | $3.00M |
| Sep 2, 2026 | Stuelpnagel John RDirector | Sale at price 60.66 - 62.61 per share. | 20K | $1.24M |
| Aug 31, 2026 | Saxonov Serge WilsonChief Executive Officer | Stock Gift at price 0.00 per share. | 100 | — |
| Aug 25, 2026 | Saxonov Serge WilsonChief Executive Officer | Sale at price 63.02 - 64.75 per share. | 10.5K | $667.90K |
| Aug 23, 2026 | Hindson Benjamin JPresident | Sale at price 63.02 per share. | 13.8K | $870.86K |
| Aug 23, 2026 | Taich AdamChief Financial Officer | Sale at price 63.02 per share. | 17.2K | $1.08M |
| Aug 23, 2026 | Suliman ShehnaazDirector | Sale at price 62.73 - 63.97 per share. | 2.2K | $140.48K |
| Aug 23, 2026 | Saxonov Serge WilsonChief Executive Officer | Sale at price 63.02 per share. | 18.5K | $1.17M |
| Aug 19, 2026 | Saxonov Serge WilsonChief Executive Officer | Stock Gift at price 0.00 per share. | 4K | — |
| Aug 13, 2026 | Teichmann Sarah A.Director | Sale at price 57.15 - 57.29 per share. | 7.6K | $432.28K |
| Aug 10, 2026 | Stuelpnagel John RDirector | Sale at price 57.58 - 58.72 per share. | 20K | $1.16M |
| Jun 21, 2026 | Saxonov Serge WilsonChief Executive Officer | Sale at price 33.29 - 36.16 per share. | 30K | $1.03M |
| Jun 15, 2026 | Suliman ShehnaazDirector | Sale at price 32.59 - 33.27 per share. | 5.7K | $186.76K |
| Jun 3, 2026 | Suliman ShehnaazDirector | Stock Award(Grant) at price 0.00 per share. | 8.8K | — |
| Jun 3, 2026 | Teichmann Sarah A.Director | Stock Award(Grant) at price 0.00 per share. | 8.8K | — |
| Jun 3, 2026 | Popovits Kimberly JDirector | Stock Award(Grant) at price 0.00 per share. | 8.8K | — |
| Jun 3, 2026 | Stuelpnagel John RDirector | Stock Award(Grant) at price 0.00 per share. | 8.8K | — |
| Jun 3, 2026 | Mateo Alan V.Director | Stock Award(Grant) at price 0.00 per share. | 8.8K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 23.9 | 14.1 | -7.9 | 3.9 | 28.4 | 35.5 | 23.3 | 32.1 | 44.7 | -16.8 | +361.0% | ||
| 2025 | 4.5 | -28.7 | -18.3 | -5.3 | 15.2 | 21.5 | 16.1 | 4.2 | -16.6 | 16.7 | 37.9 | -13.3 | +13.6% |
| 2024 | -25.5 | 11.9 | -19.5 | -22.0 | -23.4 | -13.2 | 6.3 | 13.0 | -3.3 | -29.0 | -0.8 | -9.7 | −74.3% |
| 2023 | 28.5 | 1.5 | 17.4 | -6.0 | 0.1 | 6.4 | 12.8 | -17.7 | -20.4 | -14.5 | 23.4 | 28.6 | +53.6% |
| 2022 | -35.4 | -15.4 | -6.6 | -37.2 | 7.2 | -11.6 | -11.3 | -17.8 | -13.7 | -4.6 | 42.2 | -5.7 | −75.5% |
| 2021 | 20.9 | 4.0 | 1.7 | 9.3 | -9.0 | 8.8 | -6.4 | -4.0 | -17.2 | 10.8 | -5.2 | -2.5 | +5.2% |
| 2020 | 19.9 | -12.8 | -21.8 | 28.2 | -2.4 | 14.5 | 10.1 | 16.5 | 8.8 | 9.8 | 11.8 | -7.5 | +85.7% |
| 2019 | 15.1 | 11.9 | 17.5 | +51.3% |
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Buy / hold / sell counts
No recent headlines.